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DegradationHistone deacetylase 4 (HDAC4) is a critical negative regulator for chondrocyte hypertrophy by binding to and
inhibiting Runx2, a critical transcription factor for chondrocyte hypertrophy. It is unclear howHDAC4 expression
and stability are regulatedduring growth plate development.We report here that inhibition ofmitogen-activated
protein kinase (MAPK) p38 by dominant negative p38 or p38 inhibitor prevents HDAC4 degradation.Mutation of
a potential caspase-2 and 3 cleavage site Asp289 stabilizes HDAC4 in chondrocytes. In contrast, constitutively
active MAPK kinase 6 (constitutive activator of p38) transgenic mice exhibit decreased HDAC4 content in vivo.
We also observed that p38 stimulates caspase-3 activity in chondrocytes. Inhibition of p38 or caspases reduced
HDAC4 degradation. HDAC4 inhibited Runx2 promoter activity in a dose-dependent manner and caspase
inhibitors further enhanced this inhibition by preventing HDAC4 degradation. Overall, these results demonstrate
that p38 promotes HDAC4 degradation by increasing caspase-mediated cleavage, which releases Runx2 from a
repressive inﬂuence of HDAC4 and promotes the chondrocyte hypertrophy and bone formation.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Histone deacetylase 4 (HDAC4) plays a key role in the regulation
of transcription, cell cycle, and development. HDAC4 activity alters
chromosome structure and affects transcription factor access to DNA,
as well as represses transcription when tethered to a promoter.
Studies have shown that HDAC4 regulates bone and muscle develop-
ment [1,11–14]. HDAC4 and Runx2 complexes have been shown to be
critical for bone development. Complete loss of HDAC4 results in pre-
mature ossiﬁcation of endochondral bone due to increased chondrocyte
hypertrophy and postnatal lethality due to various defects [22]. In con-
trast, overexpression of HDAC4 inhibits hypertrophy and differentia-
tion, a result which mimics a Runx2 loss-of-function phenotype [22].
Therefore, HDAC4 plays a key role in endochondral bone formation as
a negative regulator for chondrocyte hypertrophy, and its stability is
essential for controlling cell death and differentiation [17]. HDAC4 is
highly expressed in pre-hypertrophic chondrocytes and its protein
content is reduced in hypertrophic chondrocytes [6,22], but it is nots,Warren AlpertMedical School
, Suite 402H, 1 Hoppin Street,
1 401 444 6140.
thor for the study.fully understood what regulates HDAC4 expression and stability during
growth plate development.
Cernotta et al. found that serumstarvation elicits a poly-ubiquitination
and degradation of HDAC4 on serine sites for cell motility [28]. In
cardiomyocytes, Backs et al. reported that protein kinase A (PKA) regu-
lated proteolysis of HDAC4 through serine proteases [2,19]. These stud-
ies indicate that the degradation of HDAC4 is complex and regulated by
different pathways. Liu et al. reported that HDAC4 degradation is
caspase-dependent [10], which may contribute to the distribution pat-
tern of HDAC4 in hypertrophic chondrocytes. Caspases have been asso-
ciated with the degradation of HDAC4 at the Asp289 site of HDAC4 in
HeLa and IMR90-E1A cell lines [10,17]. Mutation of Asp289 or treat-
ment of caspase inhibitor could stabilizeHDAC4 [10,17]. Increase of cas-
pase activity has been documented in hypertrophic chondrocytes [4].
We have previously shown simultaneous increase in mitogen-
activated protein kinase p38 activity in hypertrophic chicken
chondrocytes [26]. Previous studies showed that mitogen-activated
protein kinase (MAPK) p38 mediates caspase-3 activity in the hippo-
campus under hypertonic stress [16] and during apoptosis induced by
singlet oxygen in human leukemia cells [27]. Thus, it is possible
that p38 also mediates caspase activity in chondrocytes, and subse-
quently regulates HDAC4 degradation through caspases. In agreement
with this hypothesis, HDAC4 protein content is remarkably decreased
in hypertrophic chondrocytes compared with pre-hypertrophic
chondrocytes [5] while both p38 activity and caspase activity are
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altered the intracellular levels of p38 and caspase activities in
chondrocytes to determine if HDAC4 degradation is affected by alter-
ation of p38 or caspase activity. If both p38 and caspases affect
HDAC4 degradation in accordance with our hypothesis, we will
investigate if p38 activates caspases and if mutation of the caspase
cleavage site (D289E) could lead to resistance to caspase or p38
mediated HDAC4 degradation in chondrocytes. The results of these
experiments will address the question of how HDAC4 is regulated
in chondrocytes and help to better understand the mechanism of
chondrocyte hypertrophy and bone formation.2. Materials and methods
2.1. Animals
Homozygous Col II/CAMKK6 transgenic (CAMKK6-TG) mice, and
their wild type (WT) littermates were euthanized at 10 days of age
(N = 4). These samples (provided by Dr. Shunichi Murakami) were a
subset of those used for a previous study and the increase of p38 activity
has been validated in vivo [25]. All experiments were approved by the
Animal Care and Use Committee of Rhode Island Hospital.2.2. Primary cell culture
Primary chondrocyte cultures were established as described previ-
ously [24]. Brieﬂy, hypertrophic chondrocytes were obtained from the
cephalic part of sterna cartilage from 17-day-old embryonic (E17)
chickens inwhich the cephalic part of sterna cartilage contains early hy-
pertrophic chondrocytes that just started to synthesize type X collagen
[3]. Cartilage pieces were incubated in Ham's F-12medium (Invitrogen,
Grand Island, NY, USA) containing 0.1% testicular hyaluronidase, 0.3%
collagenase and 0.1% trypsinase for 30 min at 37 °C, and continued to
incubate in fresh medium containing enzymes for 1 h. Cells were
collected by centrifugation and grew in F-12 medium supplemented
with 10% fetal bovine serum (FBS, Invitrogen, Grand Island, NY, USA)
at 37 °C. At about 80–90% conﬂuence, cellswere incubatedwith F12me-
dium with 0.5% FBS overnight before experiments.2.3. Western blot
The CAMKK6 cDNA was generated by replacing both phosphoryla-
tion residues Ser207 and Thr211 by Glu, and the DNp38 cDNA was
generated by replacing phosphorylation residues Thr180 and Tyr182
by Ala and Phe respectively [18]. Cells were transfected with pcDNA3
as control and construct containing HDAC4 (provided by Tony
Kouzarides) [14], CAMKK6 and DNp38 (provided by Roger Davis) [18],
D289E (provided by Claudio Brancolini) [17] at about 80% conﬂuence
and incubated for 48 h at 37 °C, with or without cycloheximide
(25 ng/ml, Sigma-Aldrich, St Louis, MO, USA), which inhibits protein
neosynthesis [10]. Cells were washed with pre-chilled PBS 3 times
and harvested with Complete Lysis-M buffer (Roche, Penzberg, Upper
Bavaria, Germany). Lysate was transferred to ice and centrifuged for
the supernatant of the homogenate. Equal amount of protein samples
was separated on a 10% SDS-PAGE gel, transferred onto a nitrocellulose
polyvinylidene diﬂuoride membrane, and probed with primary anti-
bodies against p38, phosphorylated p-38 (p-p38), HDAC4 (N-18), and
β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Detection
and signal visualization were performed using the appropriate horse-
radish peroxidase conjugated secondary antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and an ECL detection system
(Pierce, Rockford, IL, USA). The experiments were repeated 3 times
and results were similar. Averaged results were shown in the ﬁgure.2.4. Histology and immunoﬂuorescence staining
Proximal tibia growth platewas harvested fromP10mice, immersed
in 10% formalin for 24 h, and decalciﬁed in 20% EDTA solution (pH 7.2).
6-μm sections were mounted on slides. Standard Safranin-O staining
was performed to visualize morphology with a Nikon Eclipse E800
microscope (Nikon, Tokyo, Japan). Immunoﬂuorescence staining was
performed to determine HDAC4 expression in vivo. Endogenous perox-
idase was blocked by treating the sections with 3% hydrogen peroxide
(Sigma-Aldrich, St Louis, MO, USA) in methanol (Sigma-Aldrich, St
Louis, MO, USA) for 30 min. The sections were digested by 5 mg/ml hy-
aluronidase in PBS (Sigma-Aldrich, St Louis, MO, USA) for 20 min. The
sectionswere analyzed by immuno-staining using a goat polyclonal an-
tibody against HDAC4 (1:100 dilution, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) overnight at 4 °C as published before [5]. The secondary
antibody, rhodamine-conjugated donkey-anti-goat IgG (H + L)
(Jackson ImmunoResearch Laboratories, West Grove, PA, USA) was ap-
plied for 1 h. Normal goat IgG (1:1000, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) was used in place of primary antibody as negative
control. Slides weremounted and viewed under the Nikon Eclipse E800
microscope (Nikon, Tokyo, Japan). The intensity of HDAC4 signal was
quantiﬁed using Elements imaging software (NIS Nikon Eclipse 90i,
Melville, NY, USA) as the pixel unit of gray scale ﬂuorescent signal. A
representative result was shown in the ﬁgure.
2.5. Colorimetric assay
Caspase-3 activity was determined using caspase-3/CPP32 Colori-
metric Assay Kit (Biovision, Milpitas, CA, USA). Brieﬂy, hypertrophic
chondrocytes were infected with culturing medium containing the
Replication Competent Avian Splice (RCAS) vector or recombinant
RCAS viruses expressing CAMKK6 and DN p38. After 48 h, 1–5 × 106
cells were harvested with 50 μl of pre-chilled cell lysis buffer. Protein
concentration in each cell lysate sample was determined using BCA
reagent for protein quantiﬁcation. Reaction buffer containing 10 mM
DTT which protects cysteine-containing proteins was added. Cell
extracts were incubated with 5 μl of 4 mM tetrapeptide substrates
(DEVD-pNA, caspase-3) at 37 °C for 1–2 h. The reaction was measured
at 405 nm in the Spectra Max M2 Microplate Reader (Molecular
Devices, Sunnyvale, CA, USA). The experiments were repeated 3 times
and the averaged results were shown in the ﬁgure.
2.6. Realtime PCR
The quantiﬁcation of mRNA was performed by Realtime PCR using
the QuantiTect SYBR Green PCR kit (Qiagen, Valencia, CA, USA) with
the Bio-Rad CFX384 Realtime PCR Detection System (Bio-Rad, Hercules,
CA, USA). Each reaction was performed in triplicate. Chicken HDAC4
primer assay was purchased from Qiagen. Ampliﬁcation conditions
were as follows: 2minute preincubation at 50 °C, 10min at 95 °C for en-
zyme activation, and 40 cycles at 95 °C denaturation for 10 s, 55 °C an-
nealing for 30 s and 72 °C extension for 30 s. The comparative
threshold cycle (Ct)method, i.e., 2−ΔΔCt methodwas used for the calcu-
lation of fold ampliﬁcation [24]. The experimentswere repeated 3 times
and similar results were obtained. Averaged results were shown in the
ﬁgure.
2.7. Dual luciferase assay
To test the effect of HDAC4 on Runx2 activity, chicken
chondrocytes were co-transfected with pcDNA3-Runx2-Luc reporter
plasmid (100ng), pcDNA3-HDAC4plasmid (0.1 ng, encoding full length
humanHDAC4), and Renilla luciferase control plasmid (5ng) perwell in
12-well plates. After 24 h, cells were subjected to caspase-2, 3 inhibitor
treatments. Luciferase activity was assayedwith the Dual-Glo luciferase
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tory protocol.
2.8. Statistical analysis
Data were expressed as means ± standard deviation (SD). Two-
tailed paired t-tests were used to compare mRNA levels between the
caspase inhibitor treated and control groups. A probability of b5% was
considered signiﬁcant. The Runx2 promoter assay was analyzed by
one-way ANOVA with multiple pair-wise comparisons made by the
Student–Newman–Keuls method (3 comparisons or more) at a rejec-
tion level of 5% unless otherwise noted.
3. Results and discussion
3.1. Inhibition of p38 MAPK activity prevents HDAC4 degradation
To determine whether p38 regulates HDAC4 degradation, we
manipulated p38 activity by treating the cells with p38 inhibitor
SB203580 or transfecting cells with dominant negative p38 (DN p38)
or the constitutively active MAPK kinase 6 (CAMKK6). Cell lysate was
assayed using western blot to examine the p38 kinase activity and
HDAC4 degradation 2 days after transfection. Our data demonstrate
that the inhibition of p38 by overexpressing DN p38 prevents HDAC4
degradation as indicated by decreasing the HDAC4 degradation
fragment (34 kDa) compared to the empty vector control or CAMKK6
transfection (Fig. 1A and B), while increased p38 phosphorylation pre-
sents only in CAMKK6 transfected chondrocytes but not DN p38 or
empty vector control (Fig. 1D). Consistently, p38 inhibitor SB203580
also reduced the 34 kDa HDAC4 degradation fragment (Fig. 1E and F).
These observations strongly indicate that HDAC4 degradation is under
the control of p38 MAPK.
3.2. Mutation of caspase cleavage site stabilizes HDAC4 degradation in
chondrocytes
HDAC4 degradation is caspase-dependent [10]. It has been reported
that Asp289 is the primary cleavage site for caspase, and that mutation
of Asp289 or treatment of caspase inhibitor could stabilize HDAC4
in human cancer lines [10,17]. We also conﬁrmed this ﬁnding in
chondrocytes by showing that D289E mutants had less degradation
fragment of HDAC4 when compared with wild types (34 kDa)
(Fig. 2A–C). We noticed that HDAC4 degradation was signiﬁcantly
reduced but not completely disappeared (Fig. 2B), this is more likely
due to the existence of the endogenous HDAC4 rather than incom-
plete prevention of degradation, because we also observed a veryFig. 1. Inhibition of p38MAPK activity reducesHDAC4degradation. (A)DegradedHDAC4band (
of the full length HDAC4/34 kDa degradation fragment was calculated and presented. *, #, p b 0
not DNp38. (E) Chicken chondrocyteswere treatedwith p38 inhibitor SB203580 (15 μM) for 48
of full length HDAC4/degradation fragment was presented. *, p b 0.05. SB203580 (15 μM) effecthin 34 kDa band in the ﬁrst lane of Fig. 1B (without HDAC4 overex-
pression). This is consistent with the original publication fromwhich
we obtained the D289E mutant, HDAC4 degradation bands were sig-
niﬁcantly reduced, but not completely gone in the mutant as well
[17]. Since we discovered that inhibition of p38 activity also prevents
HDAC4 degradation (Fig. 1E and F), and it has been reported that the
increase of caspase and p38 activities co-exists in hypertrophic
chondrocytes [4,26], we speculate that p38 mediates HDAC4 degra-
dation at the Asp289 site through up-regulation of caspases. To test
this possibility, we determined caspase-3 activity in treated cells in
which p38 activities were manipulated. Caspase-3 activity assay
showed that over-activation of p38 by CAMKK6 stimulates caspase-
3 activity while inhibition of p38 by DN p38 has the opposite effect
(Fig. 2D).
3.3. Overactivation of p38 MAPK activity leads to decreased HDAC4 protein
content in vivo
To further explore if p38 regulates HDAC4 in vivo, we examined the
expression of HDAC4 in CAMKK6 transgenic mice (CAMKK6-TG) by
immunoﬂuorescent histochemistry. The expression pattern in the
proximal tibia growth plate from 10 day postpartum (P10) mice was
compared between CAMKK6-TG mice and their wild type (WT) litter-
mates. As expected, HDAC4 expression is decreased in the pre-
hypertrophic chondrocytes in CAMKK6-TG mice compared to WT con-
trols (Fig. 3). These samples were a subset of those used for a previous
study and the increase in p38 activity has been validated in vivo [25].
3.4. HDAC4 is stabilized by caspase-2, and -3 inhibitors
HDAC4 is unusually unstable and its degradation is caspase-
dependent [10]. Our hypothesis is that the elevated p38 activity in
hypertrophic chondrocytes may induce HDAC4 degradation through
induction of caspases. To test this possibility, we treated chicken
chondrocyteswith caspase-2 and 3 inhibitors, and found that full length
HDAC4 is increased by the treatment (Fig. 4A). We noticed that
although it is clear that the full length of HDAC4 is increased in the
cells incubated with caspase inhibitors, the degradation fragment was
also increased, and perhaps even to a greater extent (Fig. 4B). One of
the possible explanations is that the accumulation of endogenous
degradation due to the increase of the total amount of HDAC4. Another
possible explanation is that the caspase inhibitors cannot stop the
caspase activity completely.
The protein pool of HDAC4 reﬂects accumulation, which is a combi-
nation of new protein synthesis and degradation. To eliminate the pos-
sibility that increased full length HDAC4 was caused by increased34kDa)was not detected inDNp38 treated cells, evenafter overexposure (B). (C) Intensity
.05. (D)Western blot showed phosphorylation of p38 (p-p38) was induced by CAMKK but
h.Western blot showed that the degraded band (34 kDa)was decreased. (F) The intensity
tively inhibited p38 phosphorylation (E).
Fig. 2.Mutation of Asp-289 stabilized HDAC4 and CaMKK6 induces caspase-3 activity in chondrocytes. (A) Schematic structure of HDAC4 revealed Asp 289 as the target of mutation to
remove caspase-2 and 3 cleavage site, and HDAC4 antibody detects both N-terminal degradation fragment and full length HDAC4. (B) Western blot shows that HDAC4 is cleaved in
WT but the mutant D289 is resistant to degradation of HDAC4. The result indicates that the degradation of HDAC4 is related to Asp289. (C) Intensity of full length HDAC4/degradation
fragment was presented. *, p b 0.05. (D) Caspase activity assays showed that over-activation of p38 by CAMKK6 stimulates caspase-3 activity while inhibition of p38 by DN p38
has the opposite effect when comparing to the empty RCAS control. Data are the means of three independent experiments, with S.D. indicated. *, p b 0.05 compared with control.
#, p b 0.05 compared with DN p38.
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and found that caspase inhibitors could still raise the amount of full length
HDAC4 (Fig. 4C) and increase the ratio of full length HDAC4/degradation
fragment (Fig. 4D), suggesting that the ratio was shifted from the
34 kDa fragment to the full length protein. To exclude the possibilityFig. 3. The expression of HDAC4 is dramatically decreased in the growth plate of CAMKK6mice.
in the pre-hypertrophic zone (red), but the expression is reduced in the hypertrophic zone. In c
pre-hypertrophic zone in comparison to the strong signal inWTmice.Magniﬁedviewof thepre-
to the boxed areas. Blue: Nucleus stained by DAPI. Red: HDAC4 stained by Rhoda mine. Purpl
obtained (N = 4). Safranin-O staining was used to show PG staining on the growth plate. (B)
than WT controls. *p b 0.05.that caspase inhibitors may increase HDAC4 transcription, HDAC4
mRNA was quantiﬁed by Realtime PCR 24 h after treating the cells
with caspase inhibitors. In agreement with our speculation, Realtime
PCR result showed that caspase inhibitors did not signiﬁcantly increase
HDAC4 transcription (Fig. 4E).(A) Immunoﬂuorescent histochemistry shows that inWTmice, HDAC4 is highly expressed
ontrast, CAMKK6 homozygotemice (CAMKK6-TG) exhibit a weaker HDAC4 staining in the
hypertrophic andhypertrophic chondrocytes fromWTandCAMKK6-TGmice corresponds
e: overlap of blue and red. Multiple animals were examined and consistent results were
Intensity of the HDAC4 signal was quantiﬁed. CAMKK6-TG mice had much lower signal
Fig. 4.HDAC4 is stabilized by caspase-2 or 3 inhibitors and by DN p38 MAPK. (A) Full length HDAC4 is stabilized by inhibition of caspase-2 or 3 as shown by western. (B) Ratio of the full
length HDAC4/degradation fragment was presented. *, p b 0.05. (C) HDAC4 is stabilized by caspase-2 and caspase-3 inhibitors or by DN p38, and cycloheximide treatment excludes the
variation of full length HDAC4 content due to protein neosynthesis. (D) Ratio of the full length HDAC4/degradation fragment was presented. *, #, p b 0.05. (E) Realtime PCR excludes the
possibility that caspase-2, 3 inhibitors may induce HDAC4 expression at the transcription level.
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through HDAC4
P38MAPK induces caspase activity.Wehypothesized that Runx2 ex-
pression depends on p38 activity/caspase pathway in hypertrophic
chondrocytes through regulating HDAC4 protein levels. To test this
hypothesis, we determined if Runx2 promoter activity is mediated by
the p38 activity/caspase pathway through suppression of HDAC4 in
hypertrophic chondrocytes. Runx2 promoter assay results showed
that inhibition of Runx2 promoter activity by HDAC4 occurs in a dose-
dependent manner in chondrocytes (Fig. 5A) and caspase-2 and 3
inhibitors further enhance HDAC4 repression on Runx2 promoter
activity (Fig. 5B).
4. Discussion
Themajority of bones in the skeleton come from endochondral ossi-
ﬁcation, including the long bones and vertebrae. This process consists of
mesenchymal condensation, chondrogenesis, chondrocyte maturation
and hypertrophy, as well as vasculogenesis and osteoblast recruitment.
HDAC4 regulates chondrocyte hypertrophy and endochondral bone for-
mation by binding to and inhibiting the activity of transcriptional factor
Runx2, which is essential to both chondrocyte and osteoblast differenti-
ation [8,22]. Jeon et al. reported that HDAC4 deacetylates Runx2 and
leads to protein degradation [7]. However, it is not clear how HDAC4
itself is regulated in chondrocytes.
To address this question, we ﬁrst set out to ﬁnd out what regulates
HDAC4. Previous studies demonstrated that p38 MAPK signaling is re-
quired for hypertrophic chondrocyte differentiation [20]. The activity
of p38 is elevated more than 10-fold in hypertrophic chondrocytes
[26], suggesting that it may play an important role in hypertrophic
chondrocyte differentiation. However, it remains unclear how the p38Fig. 5. Caspase inhibitors further suppress Runx2 promoter activity by inhibiting degrada-
tion ofHDAC4. (A) Promoter assay showed that inhibition of Runx2 promoter activity pre-
sents anHDAC4-dose-dependentmanner in chondrocytes. (B) HDAC4 inhibition of Runx2
promoter could be enhanced by caspase inhibitors via suppressing degradation of HDAC4.signaling pathway regulates chondrocyte hypertrophy. The simulta-
neous decline of HDAC4 levels in hypertrophic chondrocytes raises the
question whether the decrease in HDAC4 is due to increased p38 activ-
ity. To answer this question, we used western blot to detect changes in
HDAC4 proﬁles in chondrocytes in response to altered p38 activity. Be-
cause the amount of endogenous HDAC4 in chondrocytes may be low
and this may create difﬁculties detecting a degradation bandwithwest-
ern blotting, we employed exogenous HDAC4 to obtain a clearer degra-
dation proﬁle. Our data showed that HDAC4 degradation depends on
p38 activity in vitro (Fig. 1) and in vivo (Fig. 3).
HDAC4 is not a direct target of p38, but caspase could provide a con-
nectionbetweenHDAC4andp38because increased caspase and p38 ac-
tivities have been found in hypertrophic chondrocytes [4,26]. Previous
studies have shown that as the central effecter of apoptosis, p38 is phos-
phorylated and subsequently activates the apoptotic gene caspase-3
when cells start apoptosis, suggesting activation of p38 is closely associ-
ated with caspase-3 [15,16,23,27]. In this study we also found that the
elevated p38 activity induced by CAMKK6 increases caspase-3 activity
in chicken hypertrophic chondrocytes (Fig. 2D), suggesting that
caspase-3 activity is under control of p38. Our ﬁnding is consistent
with previous ﬁndings [15,16,23,27]. HDAC4 degradation could be
blocked by the inhibition of caspase activity [10]. Caspase-2 and
caspase-3 cleave HDAC4 in vitro and caspase-3 is critical for
HDAC4 cleavage in vivo during UV-induced apoptosis [17]. Caspase-
dependent processing of HDAC4 cleavage occurs at Asp 289 [10]. In
this study, we demonstrated that altered caspase activity could affect
HDAC4 degradation (Fig. 4), and that mutation of the caspase cleavage
site in HDAC4 (D289E) stabilized HDAC4 degradation (Fig. 2B and C).
Thus, our results suggest that elevated p38 activity in hypertrophic
chondrocytes may induce HDAC4 degradation through induction of
caspases. Meanwhile, it is interesting to note that the 34 kDa HDAC4
degradation band is increased although full length band HDAC4 is pre-
served by treatment of caspase inhibitors (Fig. 4A and B). This observa-
tion implies that HDAC4 degradation at the site Asp289may go through
a caspase-dependent pathway, or may use an unknown bypass that is
independent of caspase which would require further investigation.
Backs et al. reported that blocking of PKA inhibited degradation of
HDAC4, while blocking of other proteases had no effect [2,19]. However,
p38 and PKA function in different pathways [21], thus it is unlikely that
p38 mediates HDAC4 degradation through PKA. Ubiquitin mediates
HDAC4 degradation through cleavage on serine site under serum star-
vation condition [28], and there is no report indicating that p38 is in-
volved in this process. Thus, caspase seems to be the only connection
between elevated p38 activity and increased HDAC4 degradation in
chondrocytes. In addition to the experimental evidence supporting
the HDAC4/Runx2 interaction provided in this manuscript and by [22]
, we also showed that HDAC4 inhibits Runx2 promoter in a dose-
dependent manner [9]. Arnold et al. also showed that HDAC4
regulates the chondrocyte hypertrophy throughMEF2 [1]. Thus, the col-
lected evidences suggest that HDAC4may target bothMEF2 and Runx2
to regulate chondrocyte hypertrophy independently.
Overexpression of HDAC4 inhibits chondrocyte hypertrophy and
differentiation, which mimics a Runx2 loss-of-function phenotype [22]
. HDAC4 is considered an inhibitor of Runx2 in the regulation of
chondrocyte hypertrophy and endochondral bone formation [7,8,22].
In this study, we used the promoter assay to demonstrate that HDAC4
directly binds with the promoter region of Runx2 and inhibits its tran-
scription in a dose-dependentmanner (Fig. 5).We further demonstrate
that caspase inhibitors enhance HDAC4 inhibition on Runx2 promoter
activity by preventing HDAC4 degradation. Taken together, these ﬁnd-
ings suggest that caspase can relieve the inhibition of endogenous
Runx2 function by cleaving HDAC4.
In summary, we present the ﬁrst evidence that p38 MAPK regulates
HDAC4 degradation through caspases. Our ﬁndings suggest a model in
which HDAC4 plays a central role in the signaling cascade, connecting
the upstream p38–caspase-3 signaling pathway, and the downstream
376 J. Zhou et al. / Biochimica et Biophysica Acta 1853 (2015) 370–376transcription regulator Runx2. This p38–caspase 3–HDAC4–Runx2
signaling cascade releases HDAC4 inhibition of Runx2, which results in
the hypertrophic state of chondrocytes and bone formation. These
ﬁndings clarify the connection between p38 and HDAC4 in chondrocyte
hypertrophy and contribute to a better understanding of the fundamen-
tal mechanism of bone development.
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HDAC4 histone deacetylase 4
MAPK mitogen-activated protein kinase
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RCAS Replication Competent Avian Splice
SD standard deviation
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